Skip to main content
Testing version — LOERadar is in active testing. Features and data may change.

The Hatch-Waxman Act: ANDA Litigation and Patent Challenges

The Drug Price Competition and Patent Term Restoration Act of 1984 created the modern framework for generic drug approval and the patent challenge system that governs when generics can enter the U.S. market.

Overview of the Hatch-Waxman Act

The Hatch-Waxman Act, formally known as the Drug Price Competition and Patent Term Restoration Act of 1984, is the foundational statute governing generic drug entry in the United States. Sponsored by Senator Orrin Hatch and Representative Henry Waxman, the law struck a carefully calibrated bargain between two competing interests: making generic drugs available to consumers more quickly and affordably, while preserving meaningful patent incentives for brand-name pharmaceutical innovation.

The Act accomplished this through two main mechanisms. First, it created the Abbreviated New Drug Application (ANDA) pathway, allowing generic manufacturers to gain FDA approval by demonstrating bioequivalence to an already-approved reference listed drug (RLD) rather than repeating full-scale clinical trials. Second, it provided brand-name companies with patent term restoration to compensate for time lost during the FDA review process, and it created a system of regulatory exclusivities as additional incentives for innovation.

The ANDA Process

An Abbreviated New Drug Application is the regulatory pathway for generic drug approval. The ANDA applicant must demonstrate that its product is pharmaceutically equivalent (same active ingredient, dosage form, strength, and route of administration) and bioequivalent (same rate and extent of absorption) to the RLD. No independent clinical efficacy or safety data is required — the generic relies on the FDA's prior finding that the RLD is safe and effective.

Critically, every ANDA must include a certification for each patent listed in the Orange Book for the reference drug. These certifications determine the timeline for generic approval and the likelihood of patent litigation.

Paragraph IV Certifications

The Hatch-Waxman Act defines four types of patent certifications that an ANDA applicant must make for each Orange Book patent:

Paragraph I: No Patent Listed

The applicant certifies that no patent information has been submitted to the FDA for the reference drug. This is uncommon for branded products still under active marketing.

Paragraph II: Patent Has Expired

The applicant certifies that the listed patent has already expired. The FDA can approve the ANDA immediately (subject to any exclusivity periods).

Paragraph III: Patent Will Expire

The applicant certifies that it will not market its generic until after the patent expires. The ANDA can be approved, but the generic cannot launch until the patent expiration date.

Paragraph IV: Patent Is Invalid or Not Infringed

The applicant certifies that the listed patent is invalid, unenforceable, or will not be infringed by the generic product. This is the most consequential certification because it directly challenges the brand company's patent rights and triggers the litigation framework central to Hatch-Waxman practice.

The 30-Month Stay

When an ANDA applicant files a Paragraph IV certification, it must send notice to both the patent owner and the NDA holder (which may be the same entity). Either the patent owner or the NDA holder then has 45 days to file a patent infringement lawsuit. If suit is filed within that 45-day window, the FDA is automatically stayed from approving the ANDA for 30 months from the date the NDA holder received the Paragraph IV notice — unless the court rules on the patent dispute earlier.

The 30-month stay is one of the most powerful tools in the brand company's arsenal. It effectively delays generic competition regardless of the merits of the patent infringement claim, because the stay is triggered automatically by the filing of suit. If the brand company does not file suit within 45 days, the stay does not apply and the FDA can approve the ANDA upon the completion of its review.

Importantly, only one 30-month stay can be triggered per ANDA. If the brand company later lists additional patents and the generic makes new Paragraph IV certifications, those subsequent certifications do not trigger additional 30-month stays (a reform enacted by the Medicare Modernization Act of 2003 to prevent “evergreening” through serial patent listings).

However, the 30-month stay can apply to patents listed after the original ANDA filing, not only to patents that were in the Orange Book at the time the ANDA was submitted. When a brand company lists a new patent and the ANDA applicant must amend or supplement its application with a new Paragraph IV certification for that patent, the NDA holder can file suit within 45 days of receiving notice to trigger the 30-month stay — provided that no prior 30-month stay has already been triggered for that ANDA. This means the first certification-and-suit sequence controls: if the brand company did not litigate the original patents but later lists a new patent, the 30-month stay remains available for that subsequently listed patent. Practitioners should track not only current Orange Book patents but also the pipeline of pending patent applications that may be listed in the future, as these can materially affect the timeline for generic approval.

180-Day First-to-File Exclusivity

The Hatch-Waxman Act grants a powerful incentive to the first ANDA applicant that files a Paragraph IV certification: 180 days of marketing exclusivity during which the FDA will not approve any other ANDA for the same drug. This first-to-file (FTF) exclusivity is intended to reward the generic company that takes the financial and legal risk of challenging the brand's patents.

The 180-day period begins running on either the date of the first commercial marketing of the generic product or the date of a court decision finding the patent invalid or not infringed, whichever comes first. During this period, the first-filer and any authorized generic are the only generic versions available, creating a duopoly that typically commands higher prices than a fully competitive generic market.

First-to-file exclusivity can be forfeited under certain circumstances, including failure to market within specified timeframes, withdrawal of the ANDA, or entry into certain types of agreements with the brand company that the FTC deems anticompetitive.

PTAB and Inter Partes Review (IPR)

Since the America Invents Act (AIA) of 2011, generic companies have an alternative to district court litigation for challenging Orange Book patents: inter partes review (IPR) proceedings before the Patent Trial and Appeal Board (PTAB) at the USPTO.

IPR proceedings are faster (typically completed within 12-18 months), less expensive, and apply a lower burden of proof (preponderance of the evidence, versus clear and convincing evidence in district court). They are limited to prior art challenges (anticipation and obviousness) and cannot address issues like inequitable conduct or non-infringement.

Many Hatch-Waxman litigants now pursue a dual-track strategy: filing Paragraph IV certifications to trigger the 30-month stay and first-to-file eligibility, while simultaneously petitioning for IPR at the PTAB to challenge patent validity on a parallel track. A successful IPR can invalidate an Orange Book patent, removing it as a barrier to all pending ANDA applications.

Citizen Petitions as a Delay Tactic

Section 505(q) of the FD&C Act allows any person to file a citizen petition requesting that the FDA take or refrain from taking an action related to drug approval. While citizen petitions serve a legitimate regulatory purpose, they have been used by brand companies as a strategic tool to delay generic approvals by raising safety, bioequivalence, or labeling concerns that require FDA response before ANDA approval can proceed.

The FDA is required to respond to 505(q) petitions within 150 days and must not delay approval of a pending ANDA solely because of a pending petition. In practice, however, the review and response process can create additional delays, particularly when petitions raise novel scientific questions.

How LOERadar Monitors Hatch-Waxman Activity

LOERadar provides comprehensive monitoring of all stages of the Hatch-Waxman challenge process:

Continue Learning

Disclaimer: This content is for educational purposes only and does not constitute legal advice. Hatch-Waxman litigation strategy should be developed with qualified patent and regulatory counsel familiar with your specific situation.